EVOK - イヴォ―ク・ファ―マ （Evoke Pharma Inc.） イヴォ―ク・ファ―マEVOKのチャート
EVOKの企業情報
| symbol | EVOK |
|---|---|
| 会社名 | Evoke Pharma Inc （イヴォ―ク・ファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 イヴォーク･ファーマ(Evoke Pharma Inc.)は特殊製薬会社である。同社は主に胃腸（GI）の障害と疾患を治療する薬剤の開発に取り組む。同社は真性糖尿病を持つ女性の急性･再発糖尿病性胃不全麻痺に関連する症状の軽減向けのメトクロプラミド鼻腔用スプレーである｢EVK-001｣を開発している。同社の主要候補製品｢EVK-001｣は後期臨床試験にある。｢EVK-001｣は鼻腔内投与を通じてメトクロプラミドの全身的送達を提供するように設計された製剤である。胃不全麻痺は機械的閉塞がない場合の胃内容排出遅延という疾患である。胃不全麻痺は食品が正常より長い時間胃の中に残ることをもたらし、多様な症状を生じる。 イヴォ―ク・ファ―マは、米国の医薬品会社。主に、胃腸疾患の治療薬の研究開発に従事。中でも、糖尿病性胃不全麻痺の治療用メトクロプラミド鼻腔内投与システム｢EVK-001｣の商品化を目指し、同薬の臨床試験に焦点を当てている。本社は、カリフォルニア州ソラナ・ビ―チ。 Evoke is a specialty pharmaceutical company focused primarily on the commercialization and development of drugs to treat GI disorders and diseases. The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. |
| 本社所在地 | 420 Stevens Avenue Suite 370 Solana Beach CA 92075 USA |
| 代表者氏名 | Cam L. Garner カム・L・ガーナー |
| 代表者役職名 | Chairman and Co Founder |
| 電話番号 | +1 858-345-1494 |
| 設立年月日 | 39083 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2013年 |
| 従業員数 | － |
| url | www.evokepharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/evok |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -11.08459 |
| 終値（lastsale） | 2.58 |
| 時価総額（marketcap） | 43598553.12 |
| 時価総額 | 時価総額（百万ドル） 45.28842 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 38.75734 |
| 当期純利益 | 当期純利益（百万ドル） -9.83748 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Evoke Pharma Inc revenues was not reported. Net loss decreased 36% to $4.3M. Lower net loss reflects FV Adjustments of Financial Investments. increase from $1.8M (expense) to $436K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.48 to -$0.27. |
EVOKのテクニカル分析
EVOKのニュース
US stocks closed higher, Dow Jones up 1.09% 2023/02/01 03:36:34 InstaForex
At the close on the New York Stock Exchange, the Dow Jones rose 1.09%, the S&P 500 index rose 1.46%, the NASDAQ Composite index rose 1.67%. The leading performer among the components of the Dow Jones index today was Home Depot Inc, which gained 9.93 points or 3.16% to close at 324.17. UnitedHealth Group Incorporated rose 13.40 points or 2.76% to close at 499.19. Dow Inc rose 1.40 points or 2.42% to close at 59.35. The least gainers were Caterpillar Inc, which shed 9.21 points or 3.52% to end the session at 252.29. McDonald''s Corporation was up 3.49 points (1.29%) to close at 267.40, while International Business Machines was down 0.57 points (0.42%) to close at 134. 73. Leading gainers among the S&P 500 components in today''s trading were Smith AO Corporation, which rose 13.72% to 67.73, International Paper, which gained 10.66% to close at 41.82, and shares of PulteGroup Inc, which rose 9.42% to end the session at 56.89. The least gainers were Phillips 66, which shed 5.77% to close at 100.28.
Evoke stock rises on filing of dismissal in nasal spray Gimoti''s patent infringement case 2023/01/30 18:23:12 Seeking Alpha
Evoke Pharma (EVOK) stock rose ~4% on Monday after the company said that a joint stipulation of dismissal was filed in the Gimoti''s patent infringement case in the U.S
Deliciously stocks You Should follow: Evoke Pharma, Inc. (NASDAQ:EVOK 0.00%), NovaBay Pharmaceuticals, Inc. (AMEX:NBY 2.88%) 2023/01/18 17:57:59 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Deliciously stocks You Should follow: Evoke Pharma, Inc. (NASDAQ:EVOK 0.00%), NovaBay Pharmaceuticals, Inc. (AMEX:NBY 2.88%) appeared first on Stocks Equity .
Evoke Pharma''s Return On Capital Employed Insights 2022/12/14 14:48:46 Benzinga
According to data from Benzinga Pro, during Q3, Evoke Pharma ''s (NASDAQ: EVOK ) reported sales totaled $832 thousand. Despite a 9.83% increase in earnings, the company posted a loss of $2.01 million. In Q2, Evoke Pharma brought in $461 thousand in sales but lost $2.23 million in earnings. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth … Full story available on Benzinga.com
USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI To Treat Moderate to Severe Gastroparesis 2022/12/07 13:30:00 Wallstreet:Online
SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray, today announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,517,545 under the title “Treatment of Moderate
Evoke Pharma''s Return On Capital Employed Insights 2022/12/14 14:48:46 Benzinga
According to data from Benzinga Pro, during Q3, Evoke Pharma ''s (NASDAQ: EVOK ) reported sales totaled $832 thousand. Despite a 9.83% increase in earnings, the company posted a loss of $2.01 million. In Q2, Evoke Pharma brought in $461 thousand in sales but lost $2.23 million in earnings. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth … Full story available on Benzinga.com
USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI To Treat Moderate to Severe Gastroparesis 2022/12/07 13:30:00 Wallstreet:Online
SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray, today announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,517,545 under the title “Treatment of Moderate
Evoke Pharma to get US patent linked to nasal spray Gimoti 2022/11/30 18:42:26 Seeking Alpha
Evoke Pharma (EVOK) said the U.S. Patent and Trademark Office ((USPTO)) issued a notice of allowance for a patent application No
Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI 2022/11/30 13:30:00 Wallstreet:Online
SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray, announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 17/100,664 for GIMOTI. Once issued,
Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI® 2022/11/30 13:30:00 GlobeNewswire
SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 17/100,664 for GIMOTI. Once issued, the patent, entitled “Nasal Formulations of Metoclopramide” will expire in December 2029. This patent application is a continuation of several other U.S. patent applications filed by the company over the last decade.
Trading - Evoke Pharma, Inc. Short Interest Update 2022/05/25 22:07:10 Business Mag
Evoke Pharma, Inc. was the recipient of a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 34,800 shares, a decrease…
GeoVax, Entasis top healthcare gainers, while Nymox, Evoke Pharma lead losers'' pack 2022/05/23 14:01:40 Seeking Alpha
GeoVax Labs GOVX +39%. Entasis Therapeutics ETTX +21%. Nymox Pharmaceutical NYMX -67%. Evoke Pharma EVOK -21%.
Evoke study shows lower risk of TD among patients treated with metoclopramide 2022/05/23 13:21:53 Seeking Alpha
Evoke Pharma (EVOK) announced on Monday that a real-world data analyses showed a lower risk of tardive dyskinesia among gastroparesis patients treated with metoclopramide compared…
HIVE Blockchain Technologies, Molecular Data, Evoke Pharma among premarket losers'' pack 2022/05/23 12:18:34 Seeking Alpha
HIVE Blockchain Technologies (HIVE) -79%.Molecular Data MKD -27% on ADS ratio changeEvoke Pharma (EVOK) -22% after real-world data analysis reveals a lower risk of Tardive Dyskinesia…
Patient Experience Survey Reported Positive Findings for GIMOTI 2022/05/18 12:30:00 Wallstreet:Online
Research Study Among Patients Demonstrated Favorable Acceptance and Utilization of GIMOTI SOLANA BEACH, Calif. and CHICAGO, May 18, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA, a leading provider of global commercial services to the life science industry, today announced positive